These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 20571820

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up.
    de Castro LF, Magalhães Gonzaga MF, Naves LA, Luiz Mendonça J, Oton de Lima B, Casulari LA.
    Horm Res Paediatr; 2018; 89(1):63-70. PubMed ID: 28954263
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males.
    De Rosa M, Ciccarelli A, Zarrilli S, Guerra E, Gaccione M, Di Sarno A, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):307-13. PubMed ID: 16487441
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Different Cabergoline Effect on Metabolic and Anthropometric Parameters in Female Prolactinoma Patients Versus Idiopathic Hyperprolactinemia Patients.
    Aboelnaga MM, Eladawy EH, Elshafei MM, Abdullah N, Shaer ME.
    Endocr Metab Immune Disord Drug Targets; 2019 Mar; 19(4):511-518. PubMed ID: 30806330
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
    Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A.
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2338-43. PubMed ID: 8964874
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma.
    Colao A, Vitale G, Di Sarno A, Spiezia S, Guerra E, Ciccarelli A, Lombardi G.
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2770-5. PubMed ID: 15181056
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. High prolactin level.
    Piketty ML, Nataf F, Dilouya A, Roux FX.
    J Neurosurg; 2000 Feb; 92(2):368-9. PubMed ID: 10659034
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.